Bipolar disorder Eating disorders Pharmaceuticals 
Psychiatric Times
JUNE 23, 2025
SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.
Psychiatric Times
JULY 7, 2025
The top 4 disease states this quarter were schizophrenia (41.7%), major depressive disorder (25%), and treatment-resistant depression (16.7%), and suicidal depression (16.7%). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 23, 2025
link] Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!
Psychiatric Times
JUNE 27, 2025
She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Ms Barbee is a physician associate at Southlake Psychiatry in Davidson, North Carolina. She serves on speaker bureaus for Neurocrine Biosciences, Axsome Therapeutics, and Alkermes.
Psychiatric Times
JUNE 13, 2025
She has been on an antipsychotic medication to treat her bipolar disorder for 10 years, resulting in stability of mood symptoms that were previously poorly controlled. Teva Pharmaceuticals; 2025. How can this be? Let’s review a few case examples. Case 1 “Ms Robbins” is 49 years old and works as a bank teller. J Clin Psychiatry.
Psychiatric Times
JUNE 30, 2025
NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. Ecopipam has demonstrated long-term safety and efficacy in reducing tic severity in pediatric patients with Tourette syndrome, with no tachyphylaxis observed.
Psychiatric Times
JULY 31, 2025
Igalmi is the first and only FDA-approved orally dissolving sublingual film for mild, moderate, or severe agitation in patients with schizophrenia or bipolar I or II disorder, administered under the supervision of a health care provider.
Expert insights. Personalized for you.
Let's personalize your content